http://www.depuyhipreplacementlawsuit.com/ With complaints about the DePuy hip replacement recall continuing to escalate, Johnson & Johnson (J&J) has added another recall, this time on 200,000 syringes of its Eprex anemia drug. A New York Times analysis has estimated that the hip replacement recall would cost J&J about $1 billion. With some artificial joint manufacturers talking of offshoring in wake of medical device excise tax, J&J would be hard pressed to prove its claim that the DePuy recall is not expected to have a material adverse effect on the company’s financial position.

1. As Published on the DePuy Hip Replacement Recall Website

2. With complaints about the DePuy hip replacement
recall continuing to escalate, Johnson & Johnson
(J&J) has added another recall, this time on 200,000
syringes of its Eprex anemia drug. A New York
Times analysis has estimated that the hip
replacement recall would cost J&J about $1 billion.
With some artificial joint manufacturers talking of
offshoring in wake of medical device excise tax, J&J
would be hard pressed to prove its claim that the
DePuy recall is not expected to have a material
adverse effect on the company’s financial position.

3. The announcement of its new recall of Eprex
syringes because some batches may not be as
potent as they should be further complicates
J&J’s new statement. The company believes
that only 6,300 Eprex syringes remain on the
market with the rest already used in some 17
countries where the batches were distributed.
J&J said that no adverse events have been
reported despite this.

4. DePuy Orthopedics Inc.’s
announcement of a worldwide
recall of two of its hip
replacement systems, the ASR
XL Acetabular System and the
DePuy ASR Hip Resurfacing
Platform August of 2010 was its
most high profile recall to date.
With the British Joint Registry estimating that nearly one
third of the hip implant will fail after six years and
DePuy already accounting for 75 percent of the 5,000
complaints on hip replacement received by the U.S.
Food and Drug Administration (FDA) this year so far,
more complaints are expected to be filed. For the last
two months alone, about 700 lawsuits have also been
filed against J&J.

5. J&J has been questioned after it hired BroadSpire
Services to handle the hip replacement recall. By
putting victims under the care of doctors on J&J’s
payroll, not the patient’s own doctor, and requiring
those patients to hand over medical records the
company would not normally get a look at unless
the patient was represented by an attorney, J&J
have been accused of trying to cut on the
settlement expenses and taking advantage of
patients.

6. With the most recent one in August this year
involving almost 2.5 million packages of a Tylenol
Cold product, the Eprex incident follows a slew of
consumer-drug recalls. Bottles of its epilepsy
drug Topamax, its atypical antipsychotic Risperdal
and its HIV treatment Prezista were some other
prescription drugs pulled out by the company--as
well as leaky insulin cartridges and potentially
unsterile drug sutures.

7. J&J is continuing to overhaul its quality control
and manufacturing processes, and it's slowly
getting some long-absent consumer drugs back
to market. However, its CEO William Weldon
admitted that the company has some ground to
make up with consumers to mend its now-
tattered reputation for high-quality products.
Damage has already been done with 93,000
people worldwide having received the DePuy hip
implants despite J&J’s DePuy hip replacement
recall.